Almost as soon as Novo innovated semaglutide medications, it was evident that the new drugs would potentially result in dramatic weight loss. Novo’s first-generation obesity drug Saxenda, made from a different GLP-1 analog, was not a big hit initially. That may be because weight loss averaged...
Saxendais the version of liraglutide approved for weight loss. Like Wegovy, it can be used in adults with a BMI of 30 mg/kg² or greater, or at least 27 mg/kg², with one or more weight-related medical conditions. Adolescents who meet certain weight-related measures also qualify for ...